Sumoylation Pathway as Potential Therapeutic Targets in Cancer
1State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, #54 Xianlie South Road, Guangzhou, Guangdong 510060,. China.
Current Molecular Medicine
|December 27, 2016
Summary
Sumoylation, a protein modification, is vital for cell processes and cancer development. Targeting sumoylation offers a promising therapeutic strategy for cancer treatment and in cancer stem cells.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- Sumoylation is a crucial posttranslational modification involving the conjugation of SUMO peptides to substrates.
- This process regulates key cellular functions such as proliferation, differentiation, senescence, and apoptosis.
- Dysregulation of sumoylation is linked to tumorigenesis, with many cancers depending on its functional pathway.
Purpose of the Study:
- To review the role of sumoylation in maintaining genome stability and DNA damage response.
- To explore the therapeutic potential of targeting sumoylation in cancer.
- To discuss sumoylation's role as a synthetic lethal partner and in cancer stem cells.
Main Methods:
- Literature review of current research on sumoylation.
- Analysis of sumoylation's involvement in DNA repair mechanisms.
- Exploration of therapeutic strategies targeting the sumoylation pathway.
Main Results:
- Sumoylation plays a significant role in genome stability and DNA damage response.
- The sumoylation pathway is essential for the survival and proliferation of various cancer types.
- Sumoylation is implicated in the biology of cancer stem cells.
Conclusions:
- Sumoylation is a critical regulator of cellular processes and is frequently dysregulated in cancer.
- Targeting sumoylation presents a viable therapeutic avenue for cancer treatment, including in overcoming resistance.
- Further research into sumoylation's role in cancer stem cells could uncover novel therapeutic targets.
Related Concept Videos
03:03mTOR Signaling and Cancer Progression
5.0K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
5.0K
02:57Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
02:23Abnormal Proliferation
5.3K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.3K
01:19Interactions Between Signaling Pathways
7.6K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.6K
01:13The Proteasome
1.9K
Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
1.9K
02:18The Proteasome
10.4K
Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
10.4K